ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

KRRO Korro Bio Inc

56.48
-1.76 (-3.02%)
After Hours
Last Updated: 17:30:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 18,951
Bid Price 55.00
Ask Price 70.00
News -
Day High 58.99

Low
13.00

52 Week Range

High
97.91

Day Low 55.059
Company Name Stock Ticker Symbol Market Type
Korro Bio Inc KRRO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-1.76 -3.02% 56.48 17:30:00
Open Price Low Price High Price Close Price Prev Close
58.99 55.059 58.99 56.48 58.24
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,323 18,951 $ 56.62 $ 1,072,922 - 13.00 - 97.91
Last Trade Time Type Quantity Stock Price Currency
16:00:06 formt 186 $ 56.48 USD

Korro Bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
41.83M 738.53k - 0 -81.17M -109.91 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Korro Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No KRRO Message Board. Create One! See More Posts on KRRO Message Board See More Message Board Posts

Historical KRRO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week62.9362.9354.4458.8128,551-6.45-10.25%
1 Month67.0680.17554.4467.9133,009-10.58-15.78%
3 Months54.6397.9146.0266.0035,4891.853.39%
6 Months13.0097.9113.0053.7843,91143.48334.46%
1 Year13.0097.9113.0053.7843,91143.48334.46%
3 Years13.0097.9113.0053.7843,91143.48334.46%
5 Years13.0097.9113.0053.7843,91143.48334.46%

Korro Bio Description

Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to create functional tissue. Its product candidate FX-322 is being developed for treating sensorineural hearing loss.

Your Recent History

Delayed Upgrade Clock